WO2002087549A1 - Comprimes a liberation prolongee du type a unites multiples - Google Patents

Comprimes a liberation prolongee du type a unites multiples Download PDF

Info

Publication number
WO2002087549A1
WO2002087549A1 PCT/JP2002/004023 JP0204023W WO02087549A1 WO 2002087549 A1 WO2002087549 A1 WO 2002087549A1 JP 0204023 W JP0204023 W JP 0204023W WO 02087549 A1 WO02087549 A1 WO 02087549A1
Authority
WO
WIPO (PCT)
Prior art keywords
release
granules
sustained
immediate
release granules
Prior art date
Application number
PCT/JP2002/004023
Other languages
English (en)
Japanese (ja)
Inventor
Shinji Aoki
Original Assignee
Taisho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co., Ltd. filed Critical Taisho Pharmaceutical Co., Ltd.
Priority to JP2002584895A priority Critical patent/JP4280074B2/ja
Publication of WO2002087549A1 publication Critical patent/WO2002087549A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Definitions

  • the present invention relates to an improvement of a multiple unit type sustained release tablet. More specifically, in a multi-unit type sustained-release tablet comprising an immediate-release portion and a sustained-release portion of a drug. A multi-unit-type sustained-release tablet with an improved dissolution rate of components from the immediate-release portion. About. Background art
  • Sustained-release preparations are dosage forms whose purpose is to reduce the number of doses by controlling the release rate of the drug and to reduce the burden of taking patients.
  • the main forms of sustained-release preparations are single-unit type sustained-release tablets with a whole tablet coated with a sustained-release membrane, and multi-unit type sustained-release tablets consisting of a large number of drug-dependent particles coated with a sustained-release membrane. And are known. It is known that a multi-unit type preparation is excellent in reducing the dispersion of a drug within and between individuals.
  • a portion capable of rapidly releasing a drug (immediate release portion) can be added together with a sustained release portion, so that an effective blood concentration of the drug can be obtained and maintained quickly. it can. For example, by rapidly and slowly releasing an analgesic component, pain can be rapidly suppressed in a patient having pain due to any cause, and the pain can be suppressed for a long time.
  • sustained-release granules consist of drug substance granules coated with a sustained-release membrane as described above. Since it is manufactured, the particle size must be relatively large, and the immediate-release granules also need to use relatively large particles. Also, the sustained-release granules have a relatively uniform particle size, and are designed as hard granules to maintain the sustained-release properties. When molding into tablets, it is necessary to use quick-release granules with excellent moldability.
  • granules prepared by the fluidized bed granulation method have better compression moldability than granules prepared by other granulation methods, but the tablet disintegration time obtained by compressing the granules into tablets Is often long, which impairs the significance of blending the immediate release portion.
  • a large amount of a disintegrant is added to the immediate-release granules to enhance the disintegration properties of the tablet, it becomes difficult to increase the particle size of the granulated product (granules), and thus the sustained release with a relatively large particle size It is difficult to obtain immediate-release granules having a particle size comparable to that of the granules.
  • the amount of the binder is increased, the particle size of the granulated product (granules) can be increased, but the disintegration of the tablet again deteriorates.
  • the particle size of the sustained release granule and the quick release granule can be made substantially the same, Accordingly, it is an object of the present invention to provide a multi-unit type sustained release tablet which can obtain a good mixture of the two, can be sufficiently molded, and is excellent in disintegration, and a method for producing the same.
  • the inventor of the present invention has found that, in a multiple-feed type sustained-release tablet containing a sustained-release granule and a rapid-release granule, the granulation method and components of the rapid-release granule are appropriately selected, and By adding the binder added to the release granules as a powder, it is possible to obtain quick release granules having the same particle size as the sustained release granules and excellent in moldability, and It has been found that a good mixing of the disintegrating granules and the quick-release granules can be obtained, and that a multi-unit type sustained-release tablet which can be sufficiently molded and has excellent disintegration properties can be obtained.
  • the present invention relates to tableting granules that release a drug continuously (hereinafter, also referred to as “slow-release granules”) and tableting granules that release a drug quickly (hereinafter, “quick-release granules”). ), Wherein the immediate-release granules contain a disintegrant and a binder, and the binder is mixed in a powder state in the production of the quick-release granules. Provide a sustained release tablet.
  • the binder mixed in a powder state in the production of immediate release granules preferably has an average particle size of 100 ⁇ m or less, more preferably 75 m or less. Powder.
  • the disintegrant used in the production of the immediate release granules preferably has an average particle size of 100 ⁇ m or less, and has a low degree of substitution such as hydroxypropylcellulose, carboxymethylcellulose, and croscarmellose sodium. It is preferably one or more substances selected from the group consisting of chromium and crospovidone.
  • the binder used for producing the immediate release granules is preferably one or more substances selected from the group consisting of hydroxypropylcellulose and hydroxypropylmethylcellulose.
  • the amount of the disintegrant contained in the immediate-release granules is preferably 5 to the entire immediate-release granules.
  • the amount of the binder contained in the immediate-release granules is preferably 1 to the entire immediate-release granules.
  • the sustained-release granules preferably have an average particle diameter of 100 to 100 m, more preferably 200 to 800 ⁇ m, and The sex granules preferably have an average particle size of 100 to: LOOO m, more preferably 15 Q to 800 m.
  • the sustained release tablet of the present invention may contain a disintegrant in addition to the sustained release granules and the quick release granules.
  • the disintegrant contained in the portion other than the sustained-release granules and the immediate-release granules the same disintegrants as those used in the above-mentioned immediate-release granules can be used.
  • the present invention provides a multi-unit which comprises compression-tabletting granules for tableting (sustained-release granules) for continuously releasing a drug and granules for tableting (quick-release granules) for rapidly releasing a drug.
  • a method for producing a sustained-release tablet characterized in that the immediate-release granules contain a disintegrant and a binder, and the binder is mixed in a powder state in the production of the immediate-release granules.
  • a manufacturing method is provided. BEST MODE FOR CARRYING OUT THE INVENTION
  • the multiple-unit type sustained release tablet of the present invention comprises tableting granules (sustained release granules) that continuously release the drug and tableting granules (quick release granules) that release the drug quickly.
  • the quick release granules include a disintegrant and a binder, and the binder is mixed in a powder state in the production of the quick release granules.
  • a binder is added in a solution state as in a usual fluidized-bed granulation method when the immediate-release granules are produced by a fluidized-bed granulation method or the like. Instead, it is characterized by being added as a powder. Otherwise, it can be produced in the same manner as a conventional multi-release sustained-release tablet comprising sustained-release granules and immediate-release granules. That is, a binder is added as a powder to an active ingredient such as a drug, a disintegrant, and other additives to prepare a mixed powder.
  • immediate-release granules by a fluidized-bed granulation method.
  • the multiple-unit sustained release tablet of the present invention can be produced by mixing the additives and compressing the granule mixture. By producing as described above, the immediate release granules can be produced to a relatively large particle size comparable to that of the sustained release granules, and the rapid release granules maintain good disintegration and compression moldability. Granules.
  • the sustained-release granules and the quick-release granules are sufficiently mixed, and the multi-unit-type sustained-release tablets themselves have appropriate hardness, and Tablets with very short disintegration time. That is, in the conventional multiple unit type sustained release tablet, sufficient particle size and disintegration of the immediate release granules, which could not be achieved only by adjusting the blending amount of the disintegrant and the binder, could not be achieved. And compression moldability can be realized at the same time.
  • the effects of the present invention as described above are mainly due to the rapid release prepared by a granulation method such as a fluidized bed granulation method having the above characteristics. It is considered that the distribution of the binder in the sexual granules is different from that in the granules produced by the conventional method. That is, when a binder is dissolved in a solvent and used as a solution as in the conventional fluidized bed granulation method, the binder is uniformly distributed inside the particles such as disintegrants and active ingredients and on the entire surface. As a result, particles such as disintegrants and active ingredients adhere to each other to grow granules.
  • the amount of the binder becomes relatively large, and a large amount of the binder is present on the surface of the granules, so that dissolution and disintegration of the granules are inhibited, resulting in disintegration. It becomes granules lacking.
  • the binder added in the form of powder is distributed as powder particles on the surface of the particles of the disintegrant, active ingredient, etc., and the particles of the disintegrant, active ingredient, etc. are adhered to form granules. grow up.
  • adding a binder in a powder state means dissolving the binder in a solvent or the like.
  • the powder is added as it is without any modification, and is not particularly limited as long as it is a powder, but is usually preferably 100 // // m or less, more preferably 75 ⁇ m or less as an average particle diameter.
  • a powder having a particle size is used.
  • Immediate release granules consist of at least a disintegrant, a binder and an active ingredient.
  • Known disintegrants and binders constituting the immediate-release granules can be used.
  • disintegrants examples include corn starch, hydroxypropyl starch, starches such as partially graphitized starch and carboxymethyl starch sodium, light anhydrous silicic acid, lactose, agar powder, microcrystalline cellulose, carboxymethylcellulose.
  • binders include starches, dextrin, gum arabic, gelatin, sugars, hydroxypropyl starch, carboxymethylcellulose sodium, methylcellulose, hydroxypropylsenorelose, low-substituted hydroxypropinoresenorelose, and hydridone.
  • Roxypropinolemethinoresenorelose, etinoresenorelose, polybutylpyrrolidone, macrogol and the like can be mentioned, and one or more of these can be used. Of these, hydroxypropynolecellulose and hydroxypropylmethylcellulose are particularly preferred.
  • the active ingredient is not particularly limited as long as it is a substance which can be expected to improve dissolution by being compounded as the immediate-release part of the multiple-unit sustained-release tablet of the present invention, and various pharmaceutical compounds can be used. . Specific examples include peramide hydrochloride, acrylonol, creosote, caffeine, anhydrous caffeine, meclizine hydrochloride, diphthene hydrochloride.
  • Examples include scopolamine, vera-donna extract, vitamin B1, fursultiamine, nicotinic acid amide, ibuprofen, acetaminophen, and pseudoephrine.
  • the immediate-release granules of the multiple-unit type sustained-release tablet of the present invention may contain, if necessary, excipients such as lactose, mannite, corn starch, magnesium aluminate metasilicate, synthetic or natural gum, in addition to the above components.
  • excipients such as lactose, mannite, corn starch, magnesium aluminate metasilicate, synthetic or natural gum, in addition to the above components.
  • Lubricants such as talc, magnesium stearate, calcium stearate, etc .
  • molding aids such as Avicel
  • additives such as sugars.
  • saccharide When a saccharide is used for the quick release granules of the multiple unit type sustained release tablet of the present invention, those having a high viscosity when dissolved can perform the same function as the binder and have a disintegration property. It is not preferable because it has an adverse effect, and it is preferable to use saccharides having a high dissolution rate of lac
  • the amount of the disintegrant and the binder in the immediate-release granules is such that sufficient granule size, disintegration, and compression moldability can be obtained for the immediate-release granules produced as described above.
  • the multiple unit type sustained release tablet obtained by use is not particularly limited as long as sufficient hardness and disintegration can be obtained.
  • the amount of the disintegrant is preferably 5 to 50% by weight based on the entire immediate release granules. More preferably about 10 to 30% by weight, and the amount of the binder is preferably about 1 to 20% by weight, more preferably about 3 to 15% by weight.
  • the above components are uniformly mixed to obtain a mixed powder, and the mixed powder is granulated to obtain quick-release granules.
  • the granulation method and granulation conditions of the immediate-release granules are not particularly limited, and known granulation methods and granulation conditions generally used can be appropriately used, but granulation by a fluidized bed granulation method is preferable. .
  • Granulation by the fluidized bed granulation method can be performed using a conventional fluidized bed granulator.In the present invention, however, only a solvent such as water is sprayed on the mixed powder already containing the binder.
  • the amount of solvent such as water The same amount as when it is added as a binder solution in the subsequent fluidized-bed granulation method, or a slightly larger amount is preferable.
  • the weight ratio between the solvent and the mixed powder used can be about 1: 2, but the weight ratio of the solvent and the mixed powder during granulation is usually About 1: 9 to 2: 8.
  • the immediate-release granules produced as described above are produced in such a particle size that good mixing with the sustained-release granules can be obtained.
  • the particle size of the immediate-release granules is similar to the particle size of the sustained-release granules, and is not particularly limited as long as good mixing with the sustained-release granules is obtained. It is preferably from 20 to 200%, more preferably from 50 to 100%, of the average particle size of the granules.
  • the difference between the average particle size of the immediate release granules and the average particle size of the sustained release granules is preferably about 200 m or less, more preferably about 150 ⁇ m or less.
  • the immediate-release granules preferably have an average particle diameter of about 100 to about 100 ⁇ , more preferably about 150 to 800 m, and the average particle diameter satisfies the above conditions. It is particularly preferred that granulation is performed so as to satisfy the conditions.
  • the sustained-release granules usually have a particle diameter of about 300 to about I000 m.
  • the tablet having a hardness of 1 mm when the immediate release granules alone are tableted with an 8 mm diameter, 24 Omg Z tablets, and a tableting pressure of 2.4 MPa. It is desirable that the disintegration time be 0 kp or more, preferably 14 kp or more, and the disintegration time in the disintegration test shown in the below-mentioned examples is 20 minutes or less, preferably 10 minutes or less.
  • the sustained-release granules contained in the multi-unit type sustained-release tablet of the present invention can be the same as those used in conventional multi-unit type sustained-release tablets, and include, for example, an active ingredient and an optional ingredient.
  • a sustained-release granule obtained by coating a sustained-release film on granules (elementary granules) comprising other additives can be obtained.
  • the raw granules are optionally produced together with the active ingredient, using the same excipients, disintegrants, and lubricants as those mentioned above for the immediate-release granules, by a conventional method such as fluidized bed granulation. be able to.
  • the elementary granules include crystalline cellulose spherical granules (trade name: Self Additives such as lactose and crystalline cellulose spherical granules (trade name: non-barrel) can be used.
  • Examples of the active ingredients include the same drugs as mentioned for the immediate release granules.
  • sustained-release base constituting the sustained-release film
  • examples of the sustained-release base constituting the sustained-release film include ethyl cellulose, acrylic acid polymer and the like.
  • Specific examples of the acrylic acid polymer include those sold under the trade name Eudragit NE30D, the same RS, and the same RL.
  • ethyl cellulose is preferably used.
  • These sustained-release bases may be used alone or in combination of two or more.
  • a solvent for forming a solution or a dispersion for coating the above-mentioned sustained-release base on elementary granules a mixture of water and a lower alcohol or a lower alcohol is preferable. Ethyl alcohol is most preferred as the lower alcohol.
  • the amount of the solvent used can be a suitable amount for the desired coating.
  • the solution of the sustained-release base can be obtained by dissolving or dispersing in a solvent as described above by an ordinary method, but the sustained-release base is preferably uniformly dissolved or dispersed in the solvent. It is preferable to use a device such as a stirrer or the like to stir well.
  • a coating aid such as hardened oil, stearic acid, and cetanol
  • a plasticizer such as medium-chain fatty acid triglyceride, triacetin, triethyl citrate, and cetanol are added to the solution or dispersion of the sustained-release base.
  • the desired dissolution rate of the active ingredient in the sustained release granules varies depending on the type of the active ingredient, but the compounding ratio of the active ingredient to the sustained release base, the sustained release film thickness, the type of the sustained release base, the molecular weight, etc.
  • the dissolution rate can be adjusted by appropriately selecting For example, when the sustained release base is ethyl cellulose, the dissolution rate can be controlled by changing the molecular weight of the ethyl cellulose.
  • a composite coating machine, a tumbling fluidized coating machine, a fluidized bed coating machine and the like can be used as a method for forming a film of the sustained-release base on the elementary granules. It is also effective to carry out curing as needed. The curing is preferably performed at a temperature equal to or higher than the softening point of the sustained-release base.
  • the outer layer of the sustained-release granules is further coated with a water-soluble polymer protective film in order to further reduce the change in the elution rate of the active ingredient of the sustained-release granules by compression molding with the subsequent rapid-release granules. May be coated.
  • water-soluble polymer used in this case examples include hydroxypropylmethylsenorellose, hydroxypropylcellulose and the like.
  • the amount of the water-soluble polymer is preferably 15% by weight or less based on the sustained-release granules.
  • the multiple-unit sustained-release tablet of the present invention is produced by compression-tabletting the above-mentioned quick-release granules and sustained-release granules by a usual method using a usual mixer and tableting machine. can do.
  • the tableting pressure is not particularly limited as long as a tablet having an appropriate hardness is formed, but is usually about 0.5 to 4.0 MPa, preferably about 1.4 to 3.0 MPa.
  • the hardness of the multiple-unit type sustained-release tablet of the present invention is usually 3 kp or more, preferably 4 kp or more when the diameter of the tablet is 8 mm.
  • the compounding ratio of the immediate release granules and the sustained release granules in the multiple unit type sustained release tablets of the present invention varies depending on the rapid release and sustained release performance of the active ingredient, and both are used as tablets having appropriate hardness. There is no particular limitation as long as the tablet can be compressed, but usually, the weight ratio of the immediate release granules to the sustained release granules is about 1: 0.5 to 1: 3, preferably about 1: 0.5 to 1: 1. It is.
  • the amount of the immediate-release granules is too small, the moldability of the tablet will be deteriorated, and if the amount of the rapid-release granules is too large, the tablet will become large and it will be difficult to take the drug, or the sustained-release granules will be released quickly. Problems such as hindering collapse may occur.
  • the multiple unit type sustained release tablet of the present invention is characterized in that the binder is mixed in a powder state in the production of the quick release granules. Therefore, the present invention is directed to a multiple unit including compression and compression of granules for tableting (sustained-release granules) that continuously release a drug and granules for tableting (immediate-release granules) that release a drug rapidly.
  • G A method for producing a sustained-release tablet, characterized in that the immediate-release granules contain a disintegrant and a binder, and the binder is mixed in a powder state in the production of the immediate-release granules. Manufacturing methods are also provided. Example
  • a granulation liquid was prepared by dissolving 810 g of feninolepropanolenoamine hydrochloride and 608 g of ethyl cellulose in a mixture of 8586 g of ethanolanol and 2147 g of water.
  • 800g selfie is put into a bottom spray type fluidized bed granulation coating machine with an inner cylinder, and the previously prepared granulation liquid is sprayed at an air supply temperature of 50 ° C and a spray speed of 20-30g / min, After spraying 12000 g of the granulation liquid, it was dried for about 30 minutes at an air supply temperature of 80 ° C to obtain elementary granules before coating.
  • ethyl cellulose and 24.9 g of triethyl citrate were dissolved in a mixture of 7935 g of ethanol and 1983 g of water to obtain a sustained-release film coating solution.
  • 810 g of the raw granules before coating are put into a bottom spray type fluidized bed granulation coating machine with an inner cylinder, and the air supply temperature is set at 35 ° C and the spray speed is adjusted within the range of 20 to 30 g / min to achieve sustained release.
  • After spraying 10128 g of the film coating solution it was dried for about 20 minutes at a supply air temperature of 80 ° C. Agglomerates were removed by sieving to obtain sustained-release granules.
  • the resulting sustained release granules had an average particle size of 378 / m.
  • sustained release granules were used in the following Examples and Comparative Examples.
  • immediate release granules were prepared in the same manner as in Example 1. However, the hydroxypropyl cellulose as a binder was added by spraying instead of the water sprayed in Example 1 as a 7% aqueous solution. The resulting immediate-release granules had an average particle size of 256 m.
  • the rapid release granules 326 g, the sustained release granules 125. 5 g, magnesium stearate 2. 25 g were mixed in a plastic bag, to give granules for tableting mixture.
  • This mixture was tableted using a tableting machine Collect 12 HU manufactured by Kikusui Seisakusho (compression pressure: 2.96 MPa) to obtain a tablet having a diameter of 8 mm and a tablet weight of about 185.5 mg.
  • the hardness of the obtained tablet was about 4 kp.
  • immediate-release granules were prepared in the same procedure as in Example 1. However, the hydroxypropyl cellulose as a binder was added by spraying instead of the water sprayed in Example 1 as a 7% aqueous solution. The resulting immediate-release granules had an average particle size of 21.3 m.
  • Powders of the respective components of the formulation shown as Comparative Example 3 in Table 1 were weighed, mixed and charged into a Powrex Vertical Granulator, to which an appropriate amount of water was added and granulated. That is, granulation was performed from a powder containing a binder by a mixed granulation method. The obtained wet granules are dried using a fluid bed dryer manufactured by Huaint Int's Co., Ltd. Obtained. The resulting immediate-release granules had an average particle size of 212 m.
  • Immediate release granules were prepared using the same formulation and procedure as in Example 1. The quick release obtained The granules had an average particle size of 211 m.
  • Immediate release granules were prepared using the same formulation and procedure as in Example 1.
  • the obtained immediate-release granules had an average particle size of 218 m.
  • a multi-unit type sustained release tablet having a short disintegration time can be prepared, and a tablet which can be expected to have more rapid immediate action and sustained action can be obtained.

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des comprimés à libération prolongée du type à unités multiples constitués de granules à libération prolongée et de granules à libération rapide qui se caractérisent en ce que les granules à libération rapide contiennent un agent délitant et un liant, ledit liant étant mélangé à l'état pulvérulent dans la production des granules à libération rapide. De cette manière, on obtient des comprimés à libération prolongée du type à unités multiples qui présentent un temps de décomposition de courte durée.
PCT/JP2002/004023 2001-04-25 2002-04-23 Comprimes a liberation prolongee du type a unites multiples WO2002087549A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2002584895A JP4280074B2 (ja) 2001-04-25 2002-04-23 マルチプルユニット型徐放性錠剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-126891 2001-04-25
JP2001126891 2001-04-25

Publications (1)

Publication Number Publication Date
WO2002087549A1 true WO2002087549A1 (fr) 2002-11-07

Family

ID=18975850

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/004023 WO2002087549A1 (fr) 2001-04-25 2002-04-23 Comprimes a liberation prolongee du type a unites multiples

Country Status (2)

Country Link
JP (1) JP4280074B2 (fr)
WO (1) WO2002087549A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038339A1 (fr) * 2004-10-01 2006-04-13 Nippon Zoki Pharmaceutical Co., Ltd. Préparation pharmaceutique solide
WO2007114376A1 (fr) * 2006-03-30 2007-10-11 Nippon Zoki Pharmaceutical Co., Ltd. Preparation pharmaceutique solide
JP2009524651A (ja) * 2006-01-27 2009-07-02 シージェイ チェイルジェダン コーポレイション マルチプルユニット型徐放性経口製剤およびその製造方法
JP2009161495A (ja) * 2008-01-09 2009-07-23 Everest Pharm Industrial Co Ltd 緩慢に溶ける微粒のアスコルビン酸を含む一種の経口急速崩散錠。
JP2012224641A (ja) * 2005-09-22 2012-11-15 Intermune Inc ピルフェニドンおよび薬学的に受容可能な賦形剤のカプセル処方物
JP2013507356A (ja) * 2009-10-09 2013-03-04 ユンジン・ファーム・カンパニー・リミテッド 速効性と持続性を同時に有する薬剤学的組成物
JP2015506980A (ja) * 2012-02-08 2015-03-05 スパーナス ファーマシューティカルズ インコーポレイテッド ビロキサジンの緩和放出製剤
US9561217B2 (en) 2001-01-29 2017-02-07 Intermune, Inc. Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone
US10188637B2 (en) 2016-03-29 2019-01-29 Hoffmann-La Roche Inc. Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same
JP2020532548A (ja) * 2017-08-29 2020-11-12 コンリグ ファーマ エーピーエス トシル酸スプラタストを含む組成物
CN113634195A (zh) * 2021-09-16 2021-11-12 上海泰坦科技股份有限公司 一种新型即溶型颗粒缓冲液及其制备方法
WO2024111552A1 (fr) * 2022-11-21 2024-05-30 持田製薬株式会社 Formule solide orale
US12121523B2 (en) 2008-09-05 2024-10-22 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit/hyperactivity disorder (ADHD)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0624991A (ja) * 1991-06-20 1994-02-01 Tokyo Tanabe Co Ltd ウルソデスオキシコール酸持続性製剤
JPH09249557A (ja) * 1996-03-14 1997-09-22 Shionogi & Co Ltd 難水溶性薬物の徐放性製剤
JPH10218761A (ja) * 1997-02-07 1998-08-18 Taisho Pharmaceut Co Ltd マルチプルユニットタイプ徐放性錠剤
JPH1121233A (ja) * 1997-07-01 1999-01-26 Taisho Pharmaceut Co Ltd マルチプルユニットタイプ徐放性錠剤
JPH11139960A (ja) * 1997-09-05 1999-05-25 Takeda Chem Ind Ltd 医 薬

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0624991A (ja) * 1991-06-20 1994-02-01 Tokyo Tanabe Co Ltd ウルソデスオキシコール酸持続性製剤
JPH09249557A (ja) * 1996-03-14 1997-09-22 Shionogi & Co Ltd 難水溶性薬物の徐放性製剤
JPH10218761A (ja) * 1997-02-07 1998-08-18 Taisho Pharmaceut Co Ltd マルチプルユニットタイプ徐放性錠剤
JPH1121233A (ja) * 1997-07-01 1999-01-26 Taisho Pharmaceut Co Ltd マルチプルユニットタイプ徐放性錠剤
JPH11139960A (ja) * 1997-09-05 1999-05-25 Takeda Chem Ind Ltd 医 薬

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9561217B2 (en) 2001-01-29 2017-02-07 Intermune, Inc. Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone
JPWO2006038339A1 (ja) * 2004-10-01 2008-05-15 日本臓器製薬株式会社 固形医薬製剤
WO2006038339A1 (fr) * 2004-10-01 2006-04-13 Nippon Zoki Pharmaceutical Co., Ltd. Préparation pharmaceutique solide
JP2012224641A (ja) * 2005-09-22 2012-11-15 Intermune Inc ピルフェニドンおよび薬学的に受容可能な賦形剤のカプセル処方物
JP2009524651A (ja) * 2006-01-27 2009-07-02 シージェイ チェイルジェダン コーポレイション マルチプルユニット型徐放性経口製剤およびその製造方法
AU2007232836B2 (en) * 2006-03-30 2012-12-06 Nippon Zoki Pharmaceutical Co., Ltd. Solid pharmaceutical preparation
JP5120652B2 (ja) * 2006-03-30 2013-01-16 日本臓器製薬株式会社 固形医薬製剤
US8367107B2 (en) 2006-03-30 2013-02-05 Nippon Zoki Pharmaceutical Co., Ltd. Solid pharmaceutical preparation
WO2007114376A1 (fr) * 2006-03-30 2007-10-11 Nippon Zoki Pharmaceutical Co., Ltd. Preparation pharmaceutique solide
JP2009161495A (ja) * 2008-01-09 2009-07-23 Everest Pharm Industrial Co Ltd 緩慢に溶ける微粒のアスコルビン酸を含む一種の経口急速崩散錠。
US12121523B2 (en) 2008-09-05 2024-10-22 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit/hyperactivity disorder (ADHD)
JP2013507356A (ja) * 2009-10-09 2013-03-04 ユンジン・ファーム・カンパニー・リミテッド 速効性と持続性を同時に有する薬剤学的組成物
US9180101B2 (en) 2009-10-09 2015-11-10 Yungjin Pharm Co., Ltd. Pharmaceutical composition simultaneously having rapid-acting property and long-acting property
JP2015506980A (ja) * 2012-02-08 2015-03-05 スパーナス ファーマシューティカルズ インコーポレイテッド ビロキサジンの緩和放出製剤
US10265319B2 (en) 2012-02-08 2019-04-23 Supernus Pharmaceuticals, Inc. Formulations of viloxazine
JP2019123736A (ja) * 2012-02-08 2019-07-25 スパーナス ファーマシューティカルズ インコーポレイテッド ビロキサジンの緩和放出製剤
US10188637B2 (en) 2016-03-29 2019-01-29 Hoffmann-La Roche Inc. Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same
JP2020532548A (ja) * 2017-08-29 2020-11-12 コンリグ ファーマ エーピーエス トシル酸スプラタストを含む組成物
JP7330948B2 (ja) 2017-08-29 2023-08-22 コンリグ ファーマ エーピーエス トシル酸スプラタストを含む組成物
US11819482B2 (en) 2017-08-29 2023-11-21 Conrig Pharma Aps Composition comprising suplatast tosilate
CN113634195A (zh) * 2021-09-16 2021-11-12 上海泰坦科技股份有限公司 一种新型即溶型颗粒缓冲液及其制备方法
CN113634195B (zh) * 2021-09-16 2024-05-10 上海泰坦科技股份有限公司 一种新型即溶型颗粒缓冲液及其制备方法
WO2024111552A1 (fr) * 2022-11-21 2024-05-30 持田製薬株式会社 Formule solide orale

Also Published As

Publication number Publication date
JPWO2002087549A1 (ja) 2004-08-12
JP4280074B2 (ja) 2009-06-17

Similar Documents

Publication Publication Date Title
JP6041919B2 (ja) ８−［｛１−（３，５−ビス−（トリフルオロメチル）フェニル）−エトキシ｝−メチル］−８−フェニル−１，７−ジアザ−スピロ［４．５］デカン−２−オンの塩を含む錠剤処方物およびそれから作製される錠剤
KR100371523B1 (ko) 테오필린 서방성 정제
FI82187C (fi) Foerfarande foer framstaellning av lagerstabila snabbsoenderfallande farmaceutiska aktivaemnespresstycken.
JP2895146B2 (ja) 二重作用錠剤
JP2014012747A (ja) バルサルタンの固体経口剤形
JP2009526840A (ja) 脂肪族アミンポリマーの医薬製剤及びそれらの製造方法
WO2001013894A1 (fr) Comprime de gabapentine a proprietes physiques et chimiques ameliorees, et son procede de fabrication
JP2556623B2 (ja) 高いイブプロフェン含有量を示す顆粒状物
JP2003513882A (ja) ジバルプロエックスナトリウムの制御放出製剤
NO341321B1 (no) Preparat for oral administrering av tamsulosin-hydroklorid og granul med kontrollert frigivelsesformulering omfattende det samme
WO2002087549A1 (fr) Comprimes a liberation prolongee du type a unites multiples
WO2015110952A1 (fr) Compositions pharmaceutiques orales solides comprenant du ticagrelor ou un sel de ce dernier
WO1999053905A1 (fr) Comprimes a liberation prolongee a unites multiples
AU784128B2 (en) Ibuprofen containing active agent preparation
AU2014295100A1 (en) Antitubercular composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its process of preparation.
JP2004527458A5 (fr)
JP2020114834A (ja) セリチニブ製剤
CN109125270B (zh) 一种固体制剂及其制备方法
TWI436760B (zh) 阿利克侖之蓋崙（ｇａｌｅｎｉｃａｌ）調配物
WO1999058114A1 (fr) Comprimes a liberation prolongee, compositions d'addition et procede de production desdites compositions
JP2013023463A (ja) 生理活性物質含有粒子の製造方法
JP4206174B2 (ja) 薬物の放出を制御した速崩錠及びその製法
JP2000516601A (ja) 水溶性化合物及びセルロースを含有する粒状物
JP6297930B2 (ja) イブプロフェン含有錠剤およびその製造方法
RU2536258C1 (ru) Способ получения таблеток терифлуномида

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002584895

Country of ref document: JP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase